Zhangzhou Pientzehuang Pharmaceutical 将来の成長

Future 基準チェック /26

Zhangzhou Pientzehuang Pharmaceutical利益と収益がそれぞれ年間15.9%と12.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に21.3% 15.9%なると予測されています。

主要情報

15.9%

収益成長率

15.9%

EPS成長率

Pharmaceuticals 収益成長	19.0%
収益成長率	12.4%
将来の株主資本利益率	21.3%
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Oct 22

Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts

Aug 20

Recent updates

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

Nov 07

Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Oct 22

Estimating The Intrinsic Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)

Sep 08

Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts

Aug 20

Subdued Growth No Barrier To Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

Jul 12

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

May 27

Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Business Is Yet to Catch Up With Its Share Price

Feb 28

業績と収益の成長予測

SHSE:600436 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	14,418	4,351	4,198	3,947	11
12/31/2025	12,688	3,678	3,623	3,354	12
12/31/2024	11,277	3,153	2,862	3,011	12
9/30/2024	10,909	3,079	1,007	1,126	N/A
6/30/2024	10,664	2,978	1,116	1,220	N/A
3/31/2024	10,600	3,002	1,968	2,104	N/A
12/31/2023	10,058	2,797	2,065	2,207	N/A
9/30/2023	9,678	2,825	2,918	3,082	N/A
6/30/2023	9,317	2,699	2,719	2,877	N/A
3/31/2023	8,975	2,553	6,810	7,001	N/A
12/31/2022	8,694	2,472	6,698	6,873	N/A
9/30/2022	8,526	2,473	5,850	5,989	N/A
6/30/2022	8,595	2,631	5,406	5,544	N/A
3/31/2022	8,368	2,556	197	289	N/A
12/31/2021	8,022	2,432	370	462	N/A
9/30/2021	7,553	2,354	318	627	N/A
6/30/2021	7,113	1,922	792	1,203	N/A
3/31/2021	6,798	1,769	1,423	1,842	N/A
12/31/2020	6,511	1,672	1,048	1,467	N/A
9/30/2020	6,451	1,594	-727	-520	N/A
6/30/2020	6,074	1,493	-1,357	-1,252	N/A
3/31/2020	5,952	1,438	-1,153	-1,075	N/A
12/31/2019	5,722	1,374	-945	-879	N/A
9/30/2019	5,522	1,332	1,544	1,626	N/A
6/30/2019	5,257	1,272	1,519	1,595	N/A
3/31/2019	5,028	1,221	795	870	N/A
12/31/2018	4,766	1,143	538	612	N/A
9/30/2018	4,555	1,052	26	79	N/A
6/30/2018	4,365	991	N/A	169	N/A
3/31/2018	4,076	907	N/A	641	N/A
12/31/2017	3,714	807	N/A	677	N/A
9/30/2017	3,428	730	N/A	794	N/A
6/30/2017	3,101	664	N/A	654	N/A
3/31/2017	2,700	616	N/A	549	N/A
12/31/2016	2,309	536	N/A	395	N/A
9/30/2016	2,180	575	N/A	407	N/A
6/30/2016	2,032	520	N/A	374	N/A
3/31/2016	1,975	497	N/A	342	N/A
12/31/2015	1,886	467	N/A	306	N/A
9/30/2015	1,698	513	N/A	330	N/A
6/30/2015	1,503	474	N/A	314	N/A
3/31/2015	1,455	440	N/A	298	N/A
12/31/2014	1,454	439	N/A	264	N/A
9/30/2014	1,409	373	N/A	240	N/A
6/30/2014	1,446	422	N/A	251	N/A
3/31/2014	1,436	438	N/A	289	N/A
12/31/2013	1,396	430	N/A	274	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 600436の予測収益成長率 (年間15.9% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 600436の収益 ( 15.9% ) CN市場 ( 26.2% ) よりも低い成長が予測されています。

高成長収益: 600436の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 600436の収益 ( 12.4% ) CN市場 ( 13.8% ) よりも低い成長が予測されています。

高い収益成長: 600436の収益 ( 12.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 600436の自己資本利益率は、3年後には高くなると予測されています ( 21.3 %)

Zhangzhou Pientzehuang Pharmaceutical 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts

Price target decreased by 8.1% to CN¥302

Price target decreased to CN¥331

Price target increased to CN¥380

Price target decreased to CN¥389

Recent updates

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2024 Results on Oct 19, 2024

Investor sentiment improves as stock rises 17%

Estimating The Intrinsic Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)

Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts

New minor risk - Dividend sustainability

Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire Zhangzhou Mingyuan Spice Co., Ltd. from Zhangzhou State-owned Asset Investment Management Co., Ltd. for approximately CNY 250 million.

Second quarter 2024 earnings released: EPS: CN¥1.23 (vs CN¥1.27 in 2Q 2023)

Subdued Growth No Barrier To Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2024 Results on Aug 17, 2024

These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely

Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q1, 2024 Results on Apr 20, 2024

Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Business Is Yet to Catch Up With Its Share Price

Full year 2023 earnings released: EPS: CN¥4.61 (vs CN¥4.10 in FY 2022)

Now 21% undervalued after recent price drop

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2023 Results on Oct 21, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥1.26 (vs CN¥1.04 in 2Q 2022)

Investor sentiment improves as stock rises 15%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.1% to CN¥302

Full year 2022 earnings released: EPS: CN¥4.09 (vs CN¥4.03 in FY 2021)

Less than half of directors are independent

Price target decreased to CN¥331

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: CN¥1.22 (vs CN¥1.48 in 3Q 2021)

Now 21% undervalued after recent price drop

Price target increased to CN¥380

Price target decreased to CN¥389

Price target decreased to CN¥389

First quarter 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to CN¥460

Now 23% undervalued after recent price drop

Price target increased to CN¥435

Third quarter 2021 earnings released: EPS CN¥1.48 (vs CN¥0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

Price target increased to CN¥281

First quarter 2021 earnings released: EPS CN¥0.94 (vs CN¥0.78 in 1Q 2020)

Price target raised to CN¥315

New 90-day high: CN¥326

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: EPS CN¥2.76

New 90-day high: CN¥300

Price target raised to CN¥269

New 90-day high: CN¥252

New 90-day low: CN¥212

Third quarter earnings released

Annual earnings released: Earnings beat expectations

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2020 Results on Oct 24, 2020

New 90-day high - CN¥208

Earnings released

Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire 29.2% stake in Longhui Pharmaceutical Co., Ltd. from Longhui Group Co., Ltd. and Jinyuan Rongtai Investment Management (Ningxia) Co., Ltd.

Price target raised to CN¥163

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2020 Results on Aug 22, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘